Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00684-1/abstract?dgcid=raven_jbs_etoc_feature_lancet Aug 02, 2025 Volume 406Number 10502p417-570 +... https://www.thelancet.com/journals/lancet/issue/vol406no10502/PIIS0140-6736(25)X0031-3